News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Tom Powles: This seems an ambitious accelerated approval in UC
Photo of Tom Powles taken from bartscancer.london
Apr 8, 2024, 15:41

Tom Powles: This seems an ambitious accelerated approval in UC

Tom Powles, Director of Barts Cancer Center, recently shared on X:

“TDXD received FDA accelerated approval in HER2 IHC 3+ treatment-refractory tumors. While HER 1-3+ is common in UC, 3+ is <25% (RR-50% n=16). New treatments are welcome. Ongoing testing is needed. This seems an ambitious accelerated approval in UC.”

Tom Powles: This seems an ambitious accelerated approval in UC

Read further.
Source: Tom Powles/X

cancer Cancer research drug discovery Drugs FDA HER2 OncoDaily Oncology solid tumors TDxd Tom Powles treatment-refractory tumors UC
Special Coverage
Science
Mar 22, 2025, 09:11
Myeloma Paper of the Day, March 22nd, suggested by Robert Orlowski
Blog
Mar 22, 2025, 09:00
Andrea Anampa-Guzmán: Fantastic time at the ASCO AIOM Clinical Research Course
Blog
Mar 22, 2025, 08:43
Richard Sassun: It is time to give Tumor Deposit a proper role in the staging
Blog
Mar 22, 2025, 08:34
Registration open for the 8th "Combinations and Sequences in therapy" conference
Blog
Mar 22, 2025, 08:02
AstraZeneca announced plans to establish a new global strategic Research and Development center in Beijing
Science
Mar 22, 2025, 07:56
Leveraging Immunogenic Cell Death to Enhance the Immune Response against Malignant Pleural Mesothelioma Tumors - The Babak Lab
Blog
Mar 22, 2025, 07:49
UICC joined the Commonwealth Secretariat and the Lancet Oncology Commission in London
Blog
Mar 22, 2025, 07:42
President of Cairo University visited the Breast Cancer Hospital (NCI - New Cairo)
Blog
Mar 22, 2025, 07:31
Istvan Petak: We have officially launched BRECISE in Madrid
Science
Mar 22, 2025, 07:26
Elvina Almuradova: Cemiplimab monotherapy vs chemotherapy as a first-line treatment with advanced NSCLC with PD-L1 expression
Blog
Mar 22, 2025, 07:23
Reducing disparities in cancer prevention, screening, and access to treatment - SPCC
Science
Mar 22, 2025, 07:12
Jennifer Bires: Fertility Preservation in People with Cancer